Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152

Pragya D Yadav; Rima R Sahay; Gajanan Sapkal; Dimpal Nyayanit; Anita M Shete; Gururaj Deshpande; Deepak Y Patil; Nivedita Gupta; Sanjay Kumar; Priya Abraham; Samiran Panda; Balram Bhargava

doi:10.1093/jtm/taab154

Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152

J Travel Med. 2021 Dec 29;28(8):taab154. doi: 10.1093/jtm/taab154.

Affiliations

¹ Indian Council of Medical Research-National Institute of Virology, Pune, India.
² Indian Council of Medical Research, V. Ramalingaswami Bhawan, New Delhi, India.
³ Department of Neurosurgery, Command Hospital (Southern Command), Armed Forces Medical College, Pune, India.

Abstract

Sera of COVID-19 naive vaccinees, COVID-19 recovered cases with vaccination and breakthrough cases demonstrated 1.3, 2.5 and 1.9-fold reduction in neutralization titers against Delta and 1.5, 3.5, 2.8-fold against Delta AY.1 compared to B.1 respectively. However, high neutralization titers would still effectively protect against Delta, Delta AY.1 and B.1.617.3 variants.

Keywords: BBV152; Delta; Delta AY.1; SARS-CoV-2; neutralization; variant of concern.

MeSH terms

Antibodies, Neutralizing
COVID-19 Vaccines
COVID-19*
Humans
Neutralization Tests
SARS-CoV-2*

Substances

Antibodies, Neutralizing
COVID-19 Vaccines

Grants and funding

Indian Council of Medical Research